Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials.

摘要: Antipsychotic drugs are widely used as a first-line pharmacological approach to treat dementia-related psychiatric symptoms. However, in this population of patients, such have been associated with severe safety concerns. Hence, the aim review is asses systematically efficacy second-generation antipsychotics (SGAs) treating neuropsychiatric symptoms order establish if potential clinical benefits treatment outweigh hypothesised risks related intervention. The Cochrane Library, MEDLINE, EMBASE and PsycINFO were searched (from 1980 June 22, 2010) using terms for included (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, SGAs) indications (elderly, dementia, Alzheimer's disease). Electronic database search supplemented hand references lists electronically identified articles. Peer-reviewed, randomised, controlled trials published English investigating SGAs patients different forms dementia process. Information was drawn from 30 articles that met inclusion criteria. Nearly all reviewed studies suffer methodological limitations too draw definitive conclusions may inform decision-making Moreover, conducted similar design show conflicting results. Because their undemonstrated effectiveness, should be avoided complicated by psychotic and/or behavioural further researches urgently needed identify useful strategies can improve condition reduce burden caregivers when interventions ineffective.